The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).

āshibio has commenced subject dosing in the Phase Ib trial, ANDECA-HO, assessing the humanised antibody, andecaliximab, in ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

Teva Pharmaceutical has reported the final analysis of the PEARL Phase IV migraine prevention trial of Ajovy (fremanezumab).

Viking Therapeutics has begun the VANQUISH Phase III clinical programme of VK2735, intended for the potential treatment of ...

The US Food and Drug Administration (FDA) has approved Gilead Science’s Yeztugo for the prevention of human immunodeficiency ...

NKGen Biotech has activated two new trial sites in Canada and Florida for the Phase I/IIa study of troculeucel to treat ...